INTRODUCTION {#sec1-1}
============

Paraquat (PQ) poisoning is one of the most serious public health problems.\[[@ref1]\] All body systems, depending on the amount of ingested toxin, are involved in PQ poisoning.\[[@ref2]\] The kidney has been shown to eliminate PQ very effectively; however, some degree of renal failure is observed with acute PQ poisoning.\[[@ref3]\] The toxic compound accumulates in lung tissue where free radicals are formed and produces alveolitis followed by pulmonary fibrosis.\[[@ref4]\] In spite of different modalities, the mortality is still high in PQ poisoning.\[[@ref3][@ref4][@ref5]\]

There is no gold standard therapy for PQ poisoning. Activated charcoal or fuller earth, radiation therapy, deferoxamine, cyclophosphamide (CP), methylprednisolone (MP), Vitamin E, Vitamin C, hemoperfusion (HP), hemodialysis (HD), continuous venovenous hemofiltration (CVVH), and N-acetyl cysteine (NAC) have been used with varying degrees of success.\[[@ref6][@ref7][@ref8][@ref9][@ref10][@ref11][@ref12][@ref13][@ref14]\]

Until now, there are five meta-analyses about treatment of PQ poisoning.\[[@ref15][@ref16][@ref17][@ref18][@ref19]\] Agarwal *et al*., Li *et al*., and He *et al*. reported meta-analysis about the effect of pulse immunosuppressive and glucocorticoid therapy, which showed a beneficial effect.\[[@ref15][@ref16][@ref18]\] CVVH prolonged the survival time of the patients without significant effect on mortality.\[[@ref19]\] Li *et al*. reported a meta-analysis about the reducing effect of HP on mortality.\[[@ref17]\] However, many studies did not show the beneficial effects.\[[@ref20][@ref21][@ref22][@ref23][@ref24][@ref25][@ref26][@ref27][@ref28][@ref29][@ref30][@ref31][@ref32][@ref33][@ref34]\] Although the efficacy of pulse immunosuppressive glucocorticoid therapy, CVVH, and HP alone has been shown in above-mentioned meta-analyses, the mortality is still high in single treatment. Since PQ poisoning is a serious public health problem in many countries, we performed a meta-analyses study to see whether HP in combination with other treatments reduces the mortality of PQ poisoning more than HP alone as no reported study yet.

MATERIALS AND METHODS {#sec1-2}
=====================

The project was approved by the Institutional Ethics Committee of our university.

Search strategy {#sec2-1}
---------------

We searched Google Scholar, EMBASE, Pub Med, ISI Web of Knowledge, Cochrane, Scopus, Springer, TRIP, and ProQuest from January 2000 to August 2017. The search strategies included (paraquat) AND (poisoning OR intoxication OR toxicity OR overdose) AND (hemoperfusion OR charcoal hemoperfusion) AND (survival OR death OR mortality OR fatality) in title and abstract based on MESH/subject. The list of references for the studies identified was also examined for more relevant studies.

Data extraction and quality assessment {#sec2-2}
--------------------------------------

Inclusion criteria were studies: (1) published articles from January 2000 to August 2017, (2) research was performed on patients (both adults and children) with PQ poisoning, (3) all patients or some of them underwent charcoal HP, (4) outcomes of treatment as death or survival had been reported, and (5) the full text of the published papers was available in English.

Exclusion criteria of this study were as follows: (1) case reports and review articles and (2) studies that all patients received the same treatment. With the use of approved keywords in Mesh, the titles of articles were searched. Then, abstracts in English were extracted. Screening process was carried out by two investigators independently who were blinded to the objective of the study. The disagreements between two researchers resolved through the involvement of a third researcher in the discussion meeting by considering the reasons for study inclusion and exclusion criteria. Finally, full texts of articles were selected. In the absence of available full text, the article was requested through an E-mail from the authors, research gate, or by librarians in the Isfahan University of Medical Sciences.

We assessed articles by the Critical Appraisal Skills Program (CASP) score method to guarantee the quality of meta-analysis. In this method, the first two questions are screening questions. If the answers were "yes," it was proceeding with the remaining questions. Then, it includes 11 critical questions for randomized clinical trials (RCTs) and case--control studies\[[@ref35][@ref36]\] and 12 question for cohort studies,\[[@ref37]\] evaluating different parts of articles with the answers of "yes" or "no" or "can't tell."

Information about the publication such as name of the first author, year of publication, country of study, type of study, age, PQ concentration, sodium dithionite test, time from ingestion to admission, time to performing HP, HP duration and times, mortality, and follow-up were recorded in the tables.

All patients in the evaluated studies had received some of the following conventional therapy including gastric lavage, activated charcoal, fuller earth, diuretic, dexamethasone, Vitamin C, Vitamin E, NAC, other antioxidants, sodium bicarbonate, glutathione, hormones, cathartics, HD for a patient with acute renal failure if necessary, and other supportive care. However, with respect to using HP alone or in combination with other treatments, we categorized and analyzed our studies based on following two sets.

### Set 1: Hemoperfusion (conventional therapy + hemoperfusion) versus nonhemoperfusion (conventional therapy) {#sec3-1}

This set considers those articles compared mortality between two groups of patients; patients received HP and those not received HP. Both groups had also received conventional therapy as mentioned in the method section.

### Set 2: Hemoperfuison versus (Hemoperfuison + other treatments) {#sec3-2}

This set includes those articles compared the mortality between two groups of patients. Patients in control group received HP, and patients in study group received HP in combination with other treatments. Both groups had also received conventional therapy as mentioned in methods section.

Data analysis {#sec2-3}
-------------

The results analyzed using the comprehensive meta-analysis software version 2.0 (Biostat, Englewood, NJ, USA). Cochrane test (Q) of heterogeneity was carried out among the studies. For determining the existence of heterogeneity among studies, the significance level was considered as \<0.05. Odds ratios (ORs) or relative risk (RR) with 95% confidence intervals (CIs) using forest plot and with the fixed and random effect approach has been analyzed. Heterogeneity was measured by calculating *I*^2^. Substantial heterogeneity was indicated if *P* \< 0.05 and *I*^2^ \> 50% when a random-effects model should be selected. If homogeneity was suggested (*P* \> 0.05 and *I*^2^ \< 50%), a fixed-effects model was used. The main outcome was mortality. To investigate the publication bias, Begg\'s and Egger\'s tests were used along with funnel plot as a graphical test. 95% CI was estimated and included in forest plot.

RESULTS {#sec1-3}
=======

An initial search identified 2250 records from databases. Considering exclusion criteria, 154 articles had eligibility for full-text evaluation. One hundred and forty-two full-text articles were further excluded, and ultimately 12 articles were selected for meta-analysis including 8 retrospective, 3 RCT, and 1 case--control studies. A flow diagram that detailed the process is presented in [Figure 1](#F1){ref-type="fig"}. Quality assessment of articles showed that CASP score of all 12 articles was higher than 65 which were acceptable.

![A flowchart of literature searches in this meta-analysis](JRMS-24-2-g001){#F1}

Hemoperfusion (conventional therapy + hemoperfusion) versus nonhemoperfusion (conventional therapy) {#sec2-4}
---------------------------------------------------------------------------------------------------

The studies included in this set are summarized in [Table 1](#T1){ref-type="table"} and [Supplementary Table 1](#T2){ref-type="table"}. We found 5 articles with a total of 1311 patients.\[[@ref38][@ref39][@ref40][@ref41][@ref42]\] Eight hundred and thirty-seven patients were underwent HP, of which 592 patients died (70.72%). Four hundred and seventy-four patients did not receive HP, of which 428 patients died (90.29%). In a study of Li *et al*.,\[[@ref38]\] because of evaluation of three groups of patients, data of one group were included in this set analysis (HP vs. non-HP) and data of other groups were included in the data set of HP versus (HP + other treatments) which will be explained in the next section.

###### 

Information of articles compared patients with paraquat poisoning received hemoperfusion plus conventional therapy (Group 1: Hemoperfusion) versus those received only conventional therapy (Group 2: Nonhemoperfusion)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author/year                      Study design/area     Sample size (Group 1/Group 2)   Group 1                                                      Group 2                                                  Time to HP (h)          Duration/times of HP   Mortality(%)                                        F
  -------------------------------------- --------------------- ------------------------------- ------------------------------------------------------------ -------------------------------------------------------- ----------------------- ---------------------- --------------------------------------------------- ----------
  Rao *et al*.\[[@ref39]\]/2017          Retrospective/India   101 (63/38)                     HP + Con. (AC, GL)                                           Con. (AC, NAC, antioxidants)                             33 patients\            NM/NM                  Group 1=42.9 (HP \<6 h=6.1 and in HP \>6 h=86.20)   60 days
                                                                                                                                                                                                                     \<6 h and\                                                                                         
                                                                                                                                                                                                                     29 patients\                                                                                       
                                                                                                                                                                                                                     \>6 h                                                                                              

  Group 2=92.10                                                                                                                                                                                                                                                                                                         

  Li *et al*.\[[@ref38]\]/2016           Retrospective/China   183 (65/75)                     HP + Con. (sodium bicarbonate AC, GL, cathartic, diuresis)   Con. (sodium bicarbonate, AC, GL, cathartic, diuresis)   1-2 h after admission   3-4 h/4 times          Group 1=56.90                                       60 days

  Group 2=78.7                                                                                                                                                                                                                                                                                                          

  Jagadeesan *et al*.\[[@ref40]\]/2017   Retrospective/India   10 (5/5)                        HP + Con. (AC, GL, HD)                                       Con. (AC, GL, HD)                                        NM                      NM/NM                  Group 1=100                                         I h

  Group 2=100                                                                                                                                                                                                                                                                                                           

  Sun *et al*.\[[@ref41]\]/2016          Retrospective/Korea   788 (594/194)                   HP + Con. (GL, fuller earth, antioxidant, mannitol)          Con. (GL, fuller's earth, antioxidant, mannitol)         NM                      NM/NM                  Group 1=76.26                                       3 months

  Group 2=95.87                                                                                                                                                                                                                                                                                                         

  Lee *et al*.\[[@ref42]\]/2012          Retrospective/Korea   272 (110/162)                   HP + Con. (GL, fuller's earth, mannitol)                     Con. (GL, fuller's earth, mannitol)                      NM                      NM/NM                  Group 1=71.81                                       3 months

  Group 2=88.27                                                                                                                                                                                                                                                                                                         
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NM=Not mentioned; PQ=Paraquat; HP=Hemoperfusion; AC=Activated charcoal; GL=Gastric lavage; Con=Conventional therapy; NAC=N-acetyl cysteine; HD=Hemodialysis; IH=In hospital; F=Follow-up

###### 

Information of articles compared patients with paraquat poisoning received hemodialysis plus conventional therapy (Group 1: Hemodialysis) versus those received only conventional therapy (Group 2: Nonhemodialysis)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author/year                      Sample size (Group 1/Group 2)                Age (years)        Urine paraquat test                                                    PQ Concentration (μg/ml)   Time from ingestion to arrival (h)
  -------------------------------------- -------------------------------------------- ------------------ ---------------------------------------------------------------------- -------------------------- -----------------------------------------------------------------
  Rao *et al*.\[[@ref39]\]/2017          101/ (63/38)                                 26.97±7.679        Positive                                                               NM                         NM

  Li *et al*.\[[@ref38]\]/2016           183/(Group 1.1=65/Group 1.2=43/Group 2=75)   Median age         5-200 μg/ml                                                            Group 1=22.95±10.41        Group 1: 7.5 (0.5-20.5)/Group 2:12.2 (0.5-22.0) median ( range)

  Group 1=37                                                                                                                                                                                               

  Group 2=21.56±11.7                                                                                                                                                                                       

  Group 2=36                                                                                                                                                                                               

  Jagadeesan *et al*.\[[@ref40]\]/2017   10/(5/5)                                     Median age, 28.5   NM                                                                     NM                         2 patients\<2 h,\
                                                                                                                                                                                                           6 patients (2-6 h),\
                                                                                                                                                                                                           2 patients\>6 h

  Sun *et al*.\[[@ref41]\]/2016          788/ (594/194)                               S=47±14            Negative in 26 cases of survival and four cases of nonsurvival group   S=0.4±0.7                  S=8.7±17.2

  NS=59±16                               NS=80.3±123.1 μg/ml                          NS=6.1±14.4                                                                                                          

  Lee *et al*.\[[@ref42]\]/2012          272 (110/162)                                Median age         Positive                                                               NM                         NM

  S=49                                                                                                                                                                                                     

  NS=63                                                                                                                                                                                                    
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NM=Not mentioned in the article; S=Survived, NS=Nonsurvived, PQ=Paraquat

The mortality rate in one study was the same (100%) in both HP and non-HP groups;\[[@ref40]\] therefore, it did not presented by the software in the funnel and forest plot. The funnel plot showed no publication bias in the studies \[[Figure 2](#F2){ref-type="fig"}\]. The meta-analysis of this group showed that *I*^2^ was 32.87 (*q* = 4.46, *P* = 0.2) indicating no significant heterogeneity. Using the fixed effect, the OR was 0.20 (95% CI = 0.11--0.40) with *z* = 4.604 (*P* \< 0.0001), which showed that the mortality was less in patients received HP compared to those received only conventional treatment \[[Figure 3](#F3){ref-type="fig"}\].

![Funnel plot of hemoperfusion and conventional therapy versus conventional therapy in paraquat poisoning mortality](JRMS-24-2-g002){#F2}

![Forest plot for comparison effect of hemoperfusion and conventional therapy (Favor A) versus conventional therapy (nonhemoperfusion) (Favor B) on mortality in paraquat poisoning](JRMS-24-2-g003){#F3}

Hemoperfuison versus (Hemoperfuison + other treatments) {#sec2-5}
-------------------------------------------------------

Seven articles included in this set which their results are summarized in [Table 2](#T3){ref-type="table"} and [supplementary Table 2](#T4){ref-type="table"}.\[[@ref2][@ref38][@ref43][@ref44][@ref45][@ref46][@ref47]\] Patients in HP group received conventional therapy and HP. Patients in HP in combination with other treatment group received conventional therapy, HP, and CVVH or continuous renal replacement therapy (CRRT) or CP or/and MP or Chinese medications Xuebijing (XBJ)/Ulinastatin. Analysis of these seven articles evaluated 2881 patients. About 1689 cases were in HP group, and from them, 1174 died (69.50%), and 1192 patients were treated with HP in combination with other treatments, of which 777 died (65.18%).

###### 

Information of articles compared patients received conventional therapy plus hemoperfusion (Group 1) versus those received conventional therapy + hemoperfusion + other treatments (Group 2)

  First author/year                    Study design/area           Sample size (Group 1/Group 2)   Group 1                                                                      Group 2                                                                                      Time to HP (h)     HP duration/times                                        Mortality (%) Group 1/Group 2   F
  ------------------------------------ --------------------------- ------------------------------- ---------------------------------------------------------------------------- -------------------------------------------------------------------------------------------- ------------------ -------------------------------------------------------- ------------------------------- ----------
  Tsai *et al*.\[[@ref43]\]/2009       Case-control/Taiwan         32 (16/16)                      HP + Con. (AC)                                                               HP + MP + Con. (AC)                                                                          NM                 NM                                                       87.5/87.5                       7 days
  Koo *et al*.\[[@ref44]\]/2002        RCT (prospective)/Korea     80 (44/36)                      HP + Con. (AC or Fuller's earth, GL, DX, Vit C)                              HP + CVVH + Con. (AC or fuller's earth. HP, DX, Vit C)                                       Group 1: 6.4±3.4   6 h/1 or 2 times (Group 1*=*7.2±3.5 Group 2*=*5.5±1.7)   63.6/66.7                       3 months
  Group 2: 5.7±2.9                                                                                                                                                                                                                                                                                                                                                                       
  Gao *et al*.\[[@ref2]\]/2015         Retrospective (RCT)/China   684 (458/226)                   HP + Con. (GL, antioxidant, DX, Vit C)                                       HP + CVVH + Con. (GL, antioxidants, DX, Vit C)                                               Group 1: 4.8±2.1   6 h/1 or 2 times                                         57.4/58.4                       IH
  Group 1*=*5.6±2                                                                                                                                                                                                                                                                                                                                                                        
  Group 2: 5.2±3.7                     Group 2*=*5.3±2.3                                                                                                                                                                                                                                                                                                                                 
  Shi *et al*.\[[@ref45]\]/2015        Retrospective/china         119 (37/82)                     HP + Con. (GL, catharsis, diuresis, hormones, glutathione, and HD for ARF)   HP + XBJ, Ulinastatin + Con. ( GL, catharsis, diuresis, hormones, glutathione, HD for ARF)   NM                 2-3 h/once daily                                         70.27/46.34                     28 days
  Wu *et al*.\[[@ref46]\]/2014         Retrospective/Taiwan        1811 (1046/765)                 HP + Con.                                                                    HP + MP/CP + Con. (DX)                                                                       NM                 NM/2.0±1.4 S*=*2.4±1.6 NS*=*1.8±1.3                      75.7/70.7                       NM
  Ghorbani *et al*.\[[@ref47]\]/2015   RCT double blind/IRAN       47 (23/24)                      HP + Con. (AC, GL, and HD for renal replacement if necessary                 AC, GL, HP, and HD for renal replacement if necessary, CP, MP                                NM                 8 h/2 times                                              60.9/25                         IH
  Li *et al*.\[[@ref38]\]/2016         Retrospective/China         108 (65/43)                     HP + Con.                                                                    HP + CVVH + Con.                                                                             NM                 First day: 3-4 h/2 times next 2 day 6-8 h daily          56.90/53.50                     60 day

NM*=*Not mentioned; PQ*=*Paraquat; HP*=*Hemoperfusion; Con*=*Conventional; AC*=*Activated charcoal; GL*=*Gastric lavage; CVVH*=*Continues venovenous hemofiltration; HD*=*Hemodialysis; S*=*Survived patients; NS*=*Nonsurvived patients; DX*=*Dexamethasone; MP*=*Methyl prednisolone; CP*=*Cyclophosphamide; CRRT*=*Continues renal replacement therapy; IH*=*In hospital; F*=*Follow-up; Vit*=*Vitamin

###### 

Information of articles compared patients received conventional therapy plus hemoperfusion (Group 1) versus those received conventional therapy + hemoperfusion + other treatments (Group 2)

  First author/year                            Study design/area            Sample size (Group 1/Group 2)                Age (years)                             Urine paraquat test                                PQ concentration μg/ml)   Time from ingestion to arrival (hours)   CASPscore
  -------------------------------------------- ---------------------------- -------------------------------------------- --------------------------------------- -------------------------------------------------- ------------------------- ---------------------------------------- -----------
  Tsai *et al*.\[[@ref43]\]/2009               Case-control/Taiwan          32 (16/16)                                   Group 1=44.2±15.6                       Positive                                           Group 2: 47.8±97.3        Group 2: 6.4±4.4                         82
  Group 2=43.5±4.2                             Group 1: 17.5±20.5           Group 1: 6.7±4.8                                                                                                                                                                                           
  S=30.25±6.24                                 S=0.25±0.19                  S=3±1.41                                                                                                                                                                                                   
  NS=45.79±14.56                               NS=37.29±74.77               NS=7.04±4.57                                                                                                                                                                                               
  Koo *et al*.\[[@ref44]\]/2002                RCT (prospective)/Korea      80 (44/36)                                   Group 1=47±16                           2.3% in Group 1 and 2.8% in Group 2 was negative   NM                        NM                                       83
  Group 2=43±17                                                                                                                                                                                                                                                                        
  Gao *et al*.\[[@ref2]\]/2015                 Retrospective/ (RCT) China   684 (458/226)                                Group 1=39±15 Group 2=37±19             Group 1=0.1%                                       NM                        NM                                       87
  Group 2=0.2% was Negative                                                                                                                                                                                                                                                            
  Shi *et al*.\[[@ref45]\]/2015                Retrospective/china          119 (Group 1=37/Group 2.1=43 Group 2.2=39)   Group 1=35.25±8.75 Group 2=33.29±7.66   NM                                                 Group 1=12.26±4.59        Group 1: 12.31±8.21                      87
  Group 2=11.87±6.63                           Group 2: 10.32±6.47                                                                                                                                                                                                                     
  Wu *et al*.\[[@ref46]\]/2014                 Retrospective/Taiwan         1811 (1046/765)                              S=38.6±14.9                             NM                                                 NM                        NM                                       
  NS=50.4±17.5                                                                                                                                                                                                                                                                         
  Ghorbani *et al*.\[[@ref47]\]/2015           RCT double-blind, IRAN       47 (23/24)                                   Group 1=23.7±5                          Navy or dark                                       NM                        Group 1=11                               81
  Group 2=22.5±5                               Group 2=15                                                                                                                                                                                                                              
  Li *et al*.\[[@ref38]\]/2016                 Retrospective/China          183 (65/43)                                  NM                                      Urine paraquat concentration 5-200 μg/ml           Group 1: 22.95±10.41      Group 1: 7.5 (0.5-20.5)                  88
  Group 2: 7.8 (0.5-19.0) (median and range)                                                                                                                                                                                                                                           
  Group 2: 20.82±9.26                                                                                                                                                                                                                                                                  

S=Survivals; NS=Nonsurvivals; NM=Not mentioned in the article

Begg\'s tests showed no asymmetry among studies (Kendall\'s S statistic: 13, *P* = 0.07) indicating no publication bias. The meta-analysis showed that *I*^2^ was 45 (Q = 11, *P* = 0.1) showing no heterogeneity, so using fixed effect model, OR was 1.24 (95% CI = 1.05--1.46 and *z* = 2.58; *P* = 0.01) which showed that mortality was higher in HP group compared to HP + other treatments \[[Figure 4](#F4){ref-type="fig"}\].

![Forest plot of comparison effect of hemoperfusion (Favor A) versus hemoperfusion with other treatments (Favor B) on mortality in paraquat poisoning](JRMS-24-2-g004){#F4}

DISCUSSION {#sec1-4}
==========

Hemoperfusion versus nonhemoperfusion {#sec2-6}
-------------------------------------

Our meta-analysis results showed that mortality was less in patients underwent HP besides conventional therapy compared with those only received conventional treatment (OR: 0.20; 95% CI: 0.10--0.40). Our result is similar to previous meta-analysis.\[[@ref17]\] In Li *et al*. study, HP also reduced mortality significantly (RR: 0.60; 95% CI: 0.54--0.66) and the mortality rate was 38.4% in HP-treated patients which is lower than our analysis. Limited resources of their study which included PubMed, Web of Science and one Chinese database (China National Knowledge Infrastructure), or publication bias may be the reason.\[[@ref17]\] Although HP reduced mortality, the mortality is still high which seems that other treatments for PQ poisoning should be considered.

Hemoperfusion versus (hemoperfusion + other treatments) {#sec2-7}
-------------------------------------------------------

Our results showed patients received HP in combination with other treatments (MP/CP/CVVH/CRRT or XBJ and Ulinastatin) had less mortality compared to those received only HP. With respect to heterogeneity in this result, I^2^ was 45 showing no heterogeneity. Two studies showed different results compared with other studies. The mortality of patients received HP was not significantly different from those received HP in combination with CVVH.\[[@ref2][@ref44]\] With respect to mortality, in three studies, CVVH was the additional treatment besides HP, without any significant effect on mortality compared to those received only HP.\[[@ref2][@ref38][@ref44]\] CVVH increased the time to death in the patients. Recent meta-analysis about evaluation of the efficacy of CVVH in the treatment of PQ poisoning supports this issue.\[[@ref19]\]

In three studies, CP/MP was the combination treatments with HP, with good effect on survival.\[[@ref43][@ref46][@ref47]\] In the study of Ghorbani *et al*., the mortality rate of patients received HP/CP/MP was lower than those underwent HP only (25% vs. 60.9%).\[[@ref47]\] Wu *et al*. reported that patients received HP and MP/CP had lower mortality compared to HP alone (70.7% vs. 75.7%).\[[@ref46]\] However, Tsai *et al*. in a case--control study showed that mortality rate was not significantly different between patients received HP and those received HP and MP.\[[@ref43]\] In the Tsai study, CP was not administered for the patients which may be the reason. Wu *et al*. had investigated different treatment regimen of immunosuppressive therapy, which showed that the MP alone had the least efficacy compared to other compounds.\[[@ref46]\] Of course, the time to performing HP and HP duration has not been mentioned in these two studies which may be the limitation of their studies.\[[@ref43][@ref46]\] HP duration and early HP may have effects on more removing PQ from the body. The efficacy of MP/CP in reducing mortality has been reported in two previous meta-analyses.\[[@ref16][@ref18]\] The mortality rate had been reported 60.4% and 56.79% in the previous meta-analysis that was performed on the effect of MP and CP on PQ-poisoned patients which is high.\[[@ref16][@ref18]\] It may be due to the fact that patients in the included studies did not receive HP except in one study.\[[@ref16][@ref18]\]

Finally, XBJ/Ulinastatin in combination with HP had protective effects as well. Shi *et al*. reported that patient received HP/XBJ or Ulinastatin had lower mortality compared to HP alone (46.34% vs. 70.27%).\[[@ref45]\] Therapeutic potential of intravenous traditional Chinese has been reported in previous studies.\[[@ref48][@ref49]\]

CONCLUSION {#sec1-5}
==========

Patients received HP in combination with other treatments (MP/CP/XBJ/Ulinastatin, XBJ) had better prognosis than those received HP alone. When the other treatments are not available, the HP alone also can reduce mortality compared to conventional therapy. As the mortality is still high, an education on harmful effects of PQ ingestion for the population is necessary to reduce the PQ poisoning.

Limitations of our study are as follows: {#sec2-8}
----------------------------------------

Data regarding the time from ingestion to admission, amount, and concentration of ingested PQ, blood PQ level, and poisoning severity were not available in all included articles to be able analyze them in the meta-analysisThe other potential heterogeneity sources such as time to performing HP and duration of HP therapy (short or long courses) had not been determined in all articles. Due to lack of sufficient data, we could not analyze the outcome with respect to these which can be another limitation of our study.

We may suggest performing future RCT studies considering the severity of poisoning based on blood PQ level to be able determine whether HP alone or HP with other intervention or medications reduces the mortality.
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